Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.

ABSTRACT:

Purpose

VEGF receptor (VEGFR) kinases are important drug targets in oncology that affect function of systemic endothelial cells. To discover genetic markers that affect VEGFR inhibitor pharmacodynamics, we performed a genome-wide association study of serum soluble vascular VEGFR2 concentrations [sVEGFR2], a pharmacodynamic biomarker for VEGFR2 inhibitors.

Experimental design

We conducted a genome-wide association study (GWAS) of [sVEGFR2] in 736 healthy Old Order Amish volunteers. Gene variants identified from the GWAS were genotyped serially in a cohort of 128 patients with advanced solid tumor with baseline [sVEGFR2] measurements, and in 121 patients with renal carcinoma with [sVEGFR2] measured before and during pazopanib therapy.

Results

rs34231037 (C482R) in KDR,

SUBMITTER: Maitland ML 

PROVIDER: S-EPMC4323272 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature